BCBA/NVO (BCBA/NVO)

Buenos Aires Stock Exchange: BCBA/NVO · ARS

ARS 9,125

-205.27 (-2.2%)· Recorded snapshot

Market cap	263.2T
Revenue (ttm)	74.6T
Net income (ttm)	26.4T
EPS (ttm)	ARS 856
P/E (trailing)	10.7x
P/E (forward)	11.7x
Dividend	ARS 78.5 (0.86%)
Volume	1,323

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 74.6T
Net income (ttm): 26.4T
EPS (ttm): ARS 856
P/E (trailing): 10.7x
P/E (forward): 11.7x
Market cap: 263.2T

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E11.7

P25 n/aP50 n/aP75 n/a

Trailing P/E10.7

P25 n/aP50 n/aP75 n/a

ROE59.8

P25 n/aP50 n/aP75 n/a

ROIC39.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BCBA/NVO indicators

Market & fundamental data

Available fields

220

Groups with data

Currency

DKK

Showing 220 of 220 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	ARS
Country	Denmark
Country code	AR
Earnings date	2026-11-04
Employees	66,700
Employees change	-9,506
Employees growth	-12.28%
Enterprise value	ARS 285T
Exchange	Buenos Aires Stock Exchange
Financial currency	DKK
Financial report date	2026-06-30
First seen	2026-07-12
Fiscal year end	December
Founded	1923
Industry	Drug Manufacturers - General
Is primary listing	No
ISIN number	AR0229808610
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Market cap	ARS 263.2T
Next earnings date	2026-11-04
Price	ARS 9,125.00
Price currency	ARS
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-27
Symbol	bcba/NVO
Website	https://www.novonordisk.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	25.52x
Average P/E ratio (3Y)	26.67x
Average P/E ratio (5Y)	30.16x
Earnings yield	9.39%
EV/Earnings	10.81x
EV/EBIT	7.7x
EV/EBITDA	7.09x
EV/FCF	16.6x
EV/Sales	3.77x
FCF / EV yield	6.02%
FCF yield	6.52%
Forward P/E	11.69x
Graham number	5976.29756
Graham upside	-34.51%
Lynch fair value	ARS 19,457.15
Lynch upside	113.23%
P/(FCF - SBC) ratio	15.63x
P/(OCF - SBC) ratio	8.91x
P/B ratio	5.25x
P/E ratio	10.65x
P/FCF ratio	15.33x
P/OCF ratio	8.82x
P/S ratio	3.53x
Price / tangible book value	11.72x
Price/EBITDA ratio	6.69x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	48.99%
EBITDA margin	52.72%
Effective tax rate	21.72%
FCF margin	22.77%
Gross margin	81.99%
Operating margin	48.99%
Pretax margin	45.15%
Profit margin	35.35%
Profit per employee	ARS 395.2M
Profitable quarters	164
Profitable years	41
Revenue per employee	ARS 1.1B
ROA	18.73%
ROA (5Y)	21.35%
ROCE	45.35%
ROE	59.82%
ROE (5Y)	74.56%
ROIC	39.22%
ROIC (5Y)	68.16%
SBC / revenue	0.44%
Tax / revenue	9.81%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	4.98%
EPS growth (Q)	-20.61%
EPS growth (QoQ)	-56.63%
EPS growth 10Y	14.01%
EPS growth 3Y	20.74%
EPS growth 5Y	22.33%
EPS growth years	31
FCF growth	14.3%
FCF growth (Q)	56.84%
FCF growth (QoQ)	232.92%
FCF growth 3Y	2.24%
FCF growth 5Y	9.51%
Gross profit growth	2.76%
Gross profit growth (Q)	-4.1%
Gross profit growth 3Y	16.73%
Gross profit growth 5Y	20.17%
Net income growth	4.84%
Net income growth (Q)	-20.81%
Net income growth (QoQ)	-56.77%
Net income growth 3Y	20.09%
Net income growth 5Y	21.29%
Net income growth years	38
OCF growth	7.52%
OCF growth (Q)	32.14%
OCF growth (QoQ)	129.19%
OCF growth 10Y	11.56%
OCF growth 3Y	13.7%
OCF growth 5Y	19.47%
Operating income growth	9.29%
Operating income growth (Q)	-0.18%
Operating income growth 3Y	22.91%
Operating income growth 5Y	24.43%
Revenue growth	5.61%
Revenue growth (Q)	2.12%
Revenue growth (QoQ)	-18.94%
Revenue growth 10Y	11.56%
Revenue growth 3Y	17.84%
Revenue growth 5Y	20.45%
Revenue growth quarters	2
Revenue growth years	8

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	ARS -12.7T
Depreciation and amortization	ARS 2.8T
EBIT	ARS 36.5T
EBITDA	ARS 39.3T
EPS	ARS 856.49
Financing cash flow	ARS -5T
Free cash flow	ARS 17.2T
Free cash flow minus SBC	ARS 16.8T
Gross profit	ARS 61.1T
Income taxes	ARS 7.3T
Investing cash flow	ARS -18.9T
Net borrowing	ARS 8.3T
Net cash flow	ARS 5.9T
Net income	ARS 26.4T
Operating cash flow minus SBC	ARS 29.5T
Operating income	ARS 36.5T
Revenue	ARS 74.6T
Stock-based compensation	ARS 324.9B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	4.21
Book value per share	ARS 11,313.07
Debt / EBITDA	0.8
Debt / equity	0.63
Debt / FCF	1.85
Goodwill	ARS 4.6T
Interest coverage	1,566.84
Long-term assets	ARS 86.9T
Long-term liabilities	ARS 29.9T
Net cash (debt)	ARS -21.5T
Net cash / market cap	-8.18%
Net debt / EBITDA	0.55
Net debt / equity	0.43
Net debt / FCF	1.25
Piotroski F-Score	5
Property, plant and equipment	ARS 53T
Shareholders' equity	ARS 50.1T
Tangible book value	ARS 22.5T
Tangible book value per share	ARS 5,072.75
Total assets	ARS 134.7T
Total cash	ARS 10.2T
Total debt	ARS 31.7T
Total liabilities	ARS 84.6T

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.61
Current assets	ARS 47.8T
Current liabilities	ARS 54.7T
Current ratio	0.87
Inventory turnover	1.22
Net working capital	ARS -12.9T
Quick ratio	0.64
Working capital	ARS -6.9T
Working capital turnover	-1,983.4

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.14%
Dividend growth	0%
Dividend growth years	0
Dividend payment date	2026-08-25
Dividend payment years	1
Dividend per share	ARS 78.51
Dividend yield	0.86%
Ex-dividend date	2026-08-14
Last dividend	ARS 78.51
Payout ratio	44.64%
Shareholder yield	1%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	-2.2%
1M price change	1.56%
1M total return	1.56%
1W price change	2.41%
1W total return	2.41%
20-day SMA	ARS 8,929.25
3M price change	-18.31%
3M total return	-17.34%
50-day SMA	ARS 9,605.40
52-week high	ARS 11,920.00
52-week high date	2026-07-03
52-week low	ARS 8,480.00
52-week low date	2026-10-06
All-time high	ARS 11,920.00
All-time high date	2026-07-03
All-time low	ARS 8,480.00
All-time low date	2026-10-06
Average true range (ATR)	ARS 203.41
Average volume	12.3K
Change from 52-week high	-23.45%
Change from 52-week low	7.61%
Change from all-time high	-23.45%
Change from all-time low	7.61%
Change from open	-1.78%
Day's gap	-0.43%
Dollar volume	ARS 12.1M
High price	ARS 9,300.00
Low price	ARS 9,120.00
Monthly RSI	0
Open price	ARS 9,290.00
Position in 52-week range	2.78%
Previous close	ARS 9,330.00
Price vs 20-day SMA	2.19%
Price vs 50-day SMA	-5%
Relative volume	0.11
RSI	48.27
Sharpe ratio	-0.03
Sortino ratio	0.11
Volume	1.3K
Weekly RSI	44.62

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3.2B
Shares change (QoQ)	-0.29%
Shares change (YoY)	-0.14%
Shares held by insiders	0.02%
Shares held by institutions	27.53%

Deeper analysis on BCBA/NVO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BCBA/NVO report

Is a complete BCBA/NVO research report available?

No complete published report is available for bcba/NVO (BCBA/NVO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BCBA/NVO (BCBA/NVO)

Price

Financial snapshot

Fair-value bridge

Latest news · BCBA/NVO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BCBA/NVO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BCBA/NVO

Frequently asked questions